Marc Hedrick, President & CEO of Plus Therapeutics (NASDAQ:PSTV), was a guest on Benzinga’s All-Access.

Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics with the potential to enhance clinical outcomes in patients with difficult-to-treat cancers of the central nervous system. The company’s technology allows for extremely precise radiotherapeutics.

The company recently presented data at the Society for Neuro-Oncology Conference in San Francisco. Early results from ongoing studies of the company’s lead drug candidate showed extremely promising responses from patients in phase 1.

Watch here:

Featured photo by Hans Reniers on Unsplash.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.